<?xml version="1.0" encoding="utf-8"?>
    <rss version="2.0">
      <channel xmlns:content="http://purl.org/rss/1.0/modules/content/">
        <title>Frontiers in Allergy | New and Recent Articles</title>
        <link>https://www.frontiersin.org/journals/allergy</link>
        <description>RSS Feed for Frontiers in Allergy | New and Recent Articles</description>
        <language>en-us</language>
        <generator>Frontiers Feed Generator,version:1</generator>
        <pubDate>2026-05-08T14:32:56.76+00:00</pubDate>
        <ttl>60</ttl>
        <item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/falgy.2026.1824120</guid>
        <link>https://www.frontiersin.org/articles/10.3389/falgy.2026.1824120</link>
        <title><![CDATA[Multi-targeted protection of Yuping Tongqiao against allergic rhinitis: suppression of inflammatory response via TSLP signaling and reinforcement of epithelial barrier integrity via AhR signaling]]></title>
        <pubdate>2026-05-08T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Zhixin Wang</author><author>Jingqi Cai</author><author>Jiahao Wu</author><author>Haoran Zheng</author><author>Min Shi</author><author>Yanan Tong</author><author>Yunlong Hou</author><author>Zhenhua Jia</author><author>Hui Qi</author>
        <description><![CDATA[BackgroundAllergic rhinitis (AR) is a prevalent chronic inflammatory disorder characterized by persistent inflammation and nasal epithelial barrier disruption. Restoring epithelial integrity and modulating the inflammatory cascade are considered promising therapeutic strategies for AR.PurposeThis study aims to systematically investigate the therapeutic efficacy of Yuping Tongqiao Tablet (YPTQ), a traditional Chinese medicine formula, in the treatment of AR and to decipher its potential mechanisms and active ingredients focusing on inflammation amelioration and barrier restoration.MethodsAn AR model was established in Sprague-Dawley rats that were sensitized and challenged with OVA. After intervention with different doses of YPTQ, nasal pathological injury and inflammatory cell infiltration were evaluated. In vitro, a human nasal epithelial cell (RPMI-2650) injury model was induced using house dust mites (HDM). Following YPTQ treatment, the expression levels of inflammatory factors and barrier-related proteins were assessed. Furthermore, the potential mechanisms and targets of YPTQ and its active monomers against AR were investigated by integrating network pharmacology analysis and molecular docking with in vitro experiments.ResultsIn the OVA-induced AR rat model, YPTQ effectively alleviated nasal symptoms, reduced histopathological damage and inflammatory cell infiltration, and suppressed overall inflammatory levels. In the HDM-induced RPMI-2650 cell injury model, YPTQ significantly inhibited inflammatory cytokines release and upregulated the tight junction protein ZO-1, thereby enhancing epithelial barrier function. Moreover, integrated analysis combining network pharmacology, molecular docking, and both in vitro and in vivo validation confirmed that YPTQ and its active ingredient, kaempferol, exert therapeutic effects through two main pathways. Firstly, they down-regulated the expression of TSLP and inhibited the migration of DCs, which subsequently alleviated nasal inflammation. Secondly, they up-regulated and activated the expression of AhR and the downstream CYP1A1, which in turn promoted the expression of a barrier-associated protein, contributing to the restoration of nasal epithelial barrier integrity.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/falgy.2026.1723516</guid>
        <link>https://www.frontiersin.org/articles/10.3389/falgy.2026.1723516</link>
        <title><![CDATA[Tobacco smoking and occupational hand eczema severity in a North African adult population: a cross-sectional analytical study]]></title>
        <pubdate>2026-05-07T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Kacem Imène</author><author>Chouchane Asma</author><author>Ben Yahia Mounira</author><author>Aloui Aloui</author><author>Gaddour Asma</author><author>Bouhoula Maroua</author><author>Brahem Aicha</author><author>Kalboussi Houda</author><author>Chatti Souhail</author><author>Maoua Maher</author><author>El Maalel Olfa</author><author>Mrizak Nejib</author>
        <description><![CDATA[BackgroundHand Eczema (HE) is one of the most common occupational diseases worldwide. Various lifestyle factors have been implicated in HE; however, the influence of tobacco smoking on the severity of HE has not been well studied.AimThe objective of this study is to investigate a possible association between the severity of HE and tobacco smoking.MethodsThis cross-sectional analytical study included 150 patients with HE seen at the Dermatology and Allergology Unit of the Occupational Department, Farhat Hached Teaching Hospital, Sousse, Tunisia, over a period of 20 months. Data were collected using a pre-established questionnaire completed during an interview with the patient. Tobacco use was self-reported. The assessment of HE severity was based on the Osnabrück Hand Eczema Severity Index score (OHSI). Multivariate analysis was performed using multiple binary logistic regressions. Independent variables were included in the regression models when their significance level was less than 0.2.ResultsIn total, 150 HE patients met the inclusion criteria. The mean age of our population was 41.05 (10.3) years, with a slight female predominance (51.3% vs. 49.7%) and a sex ratio of 0.94. Almost a third of participants—or 46 (30.9%)—were smokers. The average pack years of cigarette smoking was 18.56 (12.85). The OHSI score indicated severe HE in 97 patients (64.7%). In multivariate analysis, smoking (adjusted OR: 2.83, CI: 0.99–8.14, p = 0.005) and perceived stress (adjusted OR: 1.06, CI: 1 −1.13, p = 0.01) were associated with severe HE. Similarly, having a leisure activity was inversely associated with severe HE (adjusted OR: 0.18, CI: 0.06–0.50, p = 0.001]).ConclusionIt is important to consider smoking cessation as an important target in the prevention and management of HE.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/falgy.2026.1805985</guid>
        <link>https://www.frontiersin.org/articles/10.3389/falgy.2026.1805985</link>
        <title><![CDATA[Interpretable machine learning classification of cedar and cypress pollen on routine Durham slides for environmental exposure assessment]]></title>
        <pubdate>2026-05-07T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Nobuyoshi Suzuki</author><author>Kenjiro Sugiyama</author><author>Katsuhiko Kobayashi</author><author>Hisakuni Fukuoka</author><author>Yutaka Takumi</author>
        <description><![CDATA[Accurate discrimination of Cryptomeria japonica (cedar) and Chamaecyparis obtusa (cypress) pollen on routine Durham slides is clinically and environmentally important, because local pollen counts influence patient visits and regional exposure assessment. However, manual counting is time-consuming and often complicated by debris, air bubbles, and burst pollen, which is morphologically distinct from intact grains. In this methodological proof-of-concept study, we evaluated whether machine learning could classify particles cropped from real-world Durham slides collected under routine field conditions. We collected five routine slides from two sites in Nagano Prefecture and obtained 1,480 particle images categorized into five classes: cedar, cypress, burst cedar, burst cypress, and dust/miscellaneous artifacts. We extracted interpretable morphological and textural descriptors and trained a support vector machine using nested 5-fold stratified cross-validation. Using an optimized, interpretable feature set, the model achieved a macro-F1 score of 0.833 ± 0.025 and an overall accuracy of 0.863. Classification of intact cedar and cypress pollen was good, whereas discrimination between the two burst classes was more difficult. Misclassifications were concentrated mainly between cedar and cypress, and between burst cedar and morphologically similar particles such as burst cypress or dust. In contrast, dust was rarely misclassified as intact cedar or intact cypress. One-vs.-rest ROC-AUC values were high across classes (0.93–0.98), although performance was lower for burst pollen than for intact pollen. Among the extracted descriptors, size-related features, particularly area and radius, contributed most strongly to classification. These findings show that interpretable machine learning can distinguish intact cedar and cypress pollen on routine Durham slides under real-world conditions, while burst pollen remains a major source of classification difficulty. Further refinement of feature design for burst pollen will be necessary for routine application.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/falgy.2026.1812841</guid>
        <link>https://www.frontiersin.org/articles/10.3389/falgy.2026.1812841</link>
        <title><![CDATA[Case Report: Case of severe allergic reaction in a child caused by chlorhexidine skin disinfectant]]></title>
        <pubdate>2026-05-04T00:00:00Z</pubdate>
        <category>Case Report</category>
        <author>Yujing Zhao</author><author>Yingqian Zhang</author><author>Juncong Kang</author><author>Jingli Zhang</author><author>Chenchu Duan</author>
        <description><![CDATA[Chlorhexidine is extensively utilized as a skin antiseptic in routine clinical practice. In recent years, reports of life-threatening hypersensitivity reactions induced by chlorhexidine have been increasing progressively. Nevertheless, severe allergic events attributable to chlorhexidine-containing skin disinfectants are frequently misdiagnosed in clinical settings. Herein, we present a pediatric case with recurrent severe allergic reactions following exposure to chlorhexidine-based skin disinfection. This report aims to raise clinicians' awareness of chlorhexidine hypersensitivity.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/falgy.2026.1825315</guid>
        <link>https://www.frontiersin.org/articles/10.3389/falgy.2026.1825315</link>
        <title><![CDATA[Advanced maternal age and childhood allergy: marker or mechanism?]]></title>
        <pubdate>2026-05-04T00:00:00Z</pubdate>
        <category>Opinion</category>
        <author>Cristiana Indolfi</author><author>Angela Klain</author><author>Carolina Grella</author><author>Giulio Dinardo</author><author>Salvatore Cascone</author><author>Michele Miraglia del Giudice</author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/falgy.2026.1744703</guid>
        <link>https://www.frontiersin.org/articles/10.3389/falgy.2026.1744703</link>
        <title><![CDATA[Real-world retrospective study on allergy screening and its effect on specialist referral patterns]]></title>
        <pubdate>2026-05-04T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Inês Costa Farinha</author><author>Milagros Lázaro-Sastre</author><author>Rosita Castillo Loja</author><author>Adelaida Cabrera</author><author>Nerea Otero-Fernández</author><author>Elena Laffond Yges</author><author>Sonia Arriba-Méndez</author><author>Ignacio Dávila</author>
        <description><![CDATA[Introduction and ObjectivesAccurate diagnosis of IgE-mediated diseases requires identifying relevant allergens to guide appropriate clinical management and reduce healthcare costs (1). The ImmunoCAP Phadiatop (Thermo Fisher Scientific) is an in vitro assay detecting that detects IgE antibodies against a balanced mixture of common inhalant allergens, serving as a first-level screening tool for sensitization in patients with suspected airway allergies, and guiding subsequent management. This study aimed to evaluate test results, the impact on clinical decision-making, and its role in managing allergic conditions.Materials and MethodsA real-world retrospective observational study was conducted in a tertiary hospital allergy department (June 2021–June 2023). Data were collected using the Modulab Laboratory Information System (Werfen, Spain) and stored in a dissociated database. The Ethics Committee of Salamanca approved the study protocol. Phadiatop values above 0.35 PAU/l were considered positive. In case of repeated samples, the first was selected. Variables analyzed included test results, patient demographics, requesting departments, and allergy referrals, a well-balanced mixture of common inhalant allergens with regional adaptation. The allergen groups included were comprise: house dust mites, (e.g., Dermatophagoides pteronyssinus, D. farinae), pollens, from grasses (e.g., timothy, ryegrass), trees (e.g., birch, olive), and weeds (e.g., mugwort, plantain, ragweed), molds (e.g., Alternaria, Cladosporium, Aspergillus, Penicillium), and animal dander (e.g., cat, dog).ResultsThe study included 596 patients (median age 46, 64.1% female). Of these, 12.6% were under 18 years old. Most patients (95.8%) were referred from primary care, with 83.1% of them from urban areas. A total of 37.9% of patients had a positive result (median IgE 7.81 PAU/l). Most positive patients resided in urban areas (82.3%), were aged <18 years of age (p = 0.001), and were male (p < 0.001). Patients aged >59 (26.3%) presented mainly negative results (82.2%). Of the positive cases, 31.4% were referred to an allergist, with higher Phadiatop values increasing associated with increased referrals (p = 0.001).ConclusionsPhadiatop was mainly utilized in primary care. One-third of patients tested positive; of those, only one-third were referred to allergists, with higher Phadiatop values increasing associated with higher referral rates. Positivity was higher in males and younger people.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/falgy.2026.1807883</guid>
        <link>https://www.frontiersin.org/articles/10.3389/falgy.2026.1807883</link>
        <title><![CDATA[Cultural sensitivity and patient-centered care regarding incense and candle smoke emissions]]></title>
        <pubdate>2026-05-01T00:00:00Z</pubdate>
        <category>Perspective</category>
        <author>Gomeo Lam</author><author>Cameron Nejat</author><author>Mary F. Lee-Wong</author>
        <description><![CDATA[Incense and candles are commonly utilized for relaxation, deodorization, aesthetics, and religious observance. Both are used ubiquitously and viewed innocuously. However, both modalities release a multitude of compounds, including carbon monoxide, benzene, acrolein, and polycyclic aromatic hydrocarbons, that carry documented risks for cardiovascular disease, pulmonary dysfunction, and cancer. Incense particulate matter generates 45 mg/g vs. 10 mg/g from cigarette smoke. The following two clinical cases illustrate this challenge: an 87-year-old woman with chronic obstructive pulmonary disease and asthma whose acute dyspnea was temporally associated with incense burning during ancestral worship and a 31-year-old atopic asthmatic woman whose symptoms were repeatedly triggered by meditative relaxation through lighting candles. For many patients worldwide, these practices are inseparable from cultural identity and religious devotion, rendering simple cessation counseling insufficient. This article explores the current evidence on health hazards from incense and candle smoke, synthesizes their cultural and religious significance across major traditions, and proposes a structured framework for clinician communication. Practical recommendations, including electronic alternatives, burn duration reduction, improved ventilation, and culturally sensitive phrasing, are presented to help clinicians navigate these conversations effectively. A summary table comparing health risks, cultural roles, and alternative options is provided as a practical clinical reference. Recognizing the cultural and religious significance of incense and candle use across diverse populations is a prerequisite for delivering care that is both clinically effective and respectful of patient values.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/falgy.2026.1795685</guid>
        <link>https://www.frontiersin.org/articles/10.3389/falgy.2026.1795685</link>
        <title><![CDATA[Sensitization to 19 allergen sources in 2,124 children in Kashi Prefecture, China: a single-center cross-sectional retrospective study]]></title>
        <pubdate>2026-04-29T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Riziwanguli Maitusong</author><author>Asimuguli Wubuli</author><author>Ayiguli Saimaier</author><author>Lifang Li</author><author>Gumina Kamili</author><author>Muyesaier Maimaiti</author><author>Rexiati Dawuti</author>
        <description><![CDATA[ObjectivesTo investigate the sensitization to common allergen sources among children in Kashi Prefecture and offer a scientific foundation for preventing allergic diseases in this demographic.MethodsThe study retrospectively collected the detection results of serum allergen-specific IgE antibodies from 2,124 children at the First People's Hospital of Kashi Prefecture from January 2022 to December 2024.ResultsThe overall sensitization rate detected by sIgE was 42.70%. Within the sensitization cases, inhalant allergens had a sensitization rate of 29.52%. The most frequent allergen sources included tree combinations (330 cases, 15.54%), cat fur (243, 11.44%), and Artemisia argyi (195, 9.18%). The sensitization rate for food allergens was 24.01%, with egg whites (229, 10.78%), milk (130, 6.12%), and peanuts (99, 4.66%) being the most frequent sources. Sensitization to tree combinations, Ambrosia artemisiifolia, cat fur, and peanuts was significantly higher in boys compared to girls. Tree combinations, Ambrosia artemisiifolia, Artemisia argyi, house dust, cat fur, mold combinations, and Humulus scandens exhibited an increasing trend in sensitization rate with age, whereas egg whites, milk, and beef exhibited decreasing trends with age. The sensitization rates for tree combinations, house dust, and mutton displayed significant seasonal variations.ConclusionsSensitization to common allergens was prevalent among children in Kashi, although only a small number exhibited allergic symptoms. The sensitization rates for common allergens varied significantly based on sex, age and season. These results suggest that sIgE detection of specific allergens can aid in identifying triggering factors, which is crucial for preventing allergic diseases.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/falgy.2026.1819491</guid>
        <link>https://www.frontiersin.org/articles/10.3389/falgy.2026.1819491</link>
        <title><![CDATA[Emerging perspectives in respiratory allergic diseases: a review of future directions]]></title>
        <pubdate>2026-04-29T00:00:00Z</pubdate>
        <category>Review</category>
        <author>Rafael Durán</author><author>Sergio E. Chiarella</author><author>Thanai Pongdee</author><author>Juyoung Choi</author><author>Martin Maillo</author><author>Cesar A. Galván</author>
        <description><![CDATA[BackgroundRespiratory allergic diseases are experiencing changes influenced by genetic factors, environmental shifts, and social and demographic elements. These evolving patterns, together with rapid advances in diagnosis and treatment, require a thorough review of emerging trends.ObjectiveTo examine future directions in managing respiratory allergic diseases, focusing on changing disease patterns, environmental factors, diagnostic innovations, and therapeutic advances toward precision medicine. A literature search was conducted in PubMed and Scopus databases covering 2015–2025. Studies addressing human populations with allergic rhinitis or asthma were included, emphasizing emerging patterns, environmental factors, diagnostic technologies, and therapeutic innovations, while reviews, conference proceedings, case reports, and studies without clinical relevance were excluded. Initial screening identified 52 studies, and 21 additional studies were identified through complementary searches, resulting in 73 studies in the final analysis.Summary of findingsClimate change is a key factor affecting disease patterns, with pollen seasons starting 10–40 days earlier and yearly emissions increasing by up to 200%. Regarding pathogenesis, early-life rhinovirus C infections with IgE sensitization significantly increase asthma risk (HR = 4.06), while severe asthma shows 40–84% eosinophilic patterns, depending on the assessment approach. On the diagnostic front, advances include multiplex platforms, proteomic biomarkers, and microRNAs. Therapeutically, innovations encompass biologics combined with allergen immunotherapy, nanobody-based therapeutics, and microbiota interventions.ConclusionsThese developments point toward personalized management of respiratory allergic diseases. However, challenges remain in research with underrepresented populations and accessibility. Moving forward, the key priority is integrating this diverse knowledge into practical strategies that advance precision medicine in respiratory allergic diseases.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/falgy.2026.1799085</guid>
        <link>https://www.frontiersin.org/articles/10.3389/falgy.2026.1799085</link>
        <title><![CDATA[The nasal-oral microbiome axis in allergic rhinitis: environmental triggers, microbial dysbiosis, and immune dysregulation]]></title>
        <pubdate>2026-04-28T00:00:00Z</pubdate>
        <category>Review</category>
        <author>Yuan Li</author><author>Yue Sun</author><author>Lei Shi</author><author>Aiping Wang</author><author>Xue Gao</author><author>Hui Leng</author>
        <description><![CDATA[Allergic rhinitis (AR) is a common chronic inflammatory disease, which affects about 400 million people around the world. The role of the upper airway microbiota in the development of AR has recently emerged and seems to be an important player in its pathology, but there are still no detailed mechanistic models that incorporate exposure to the environment, dysbiosis of microbes or dysregulated immunity as a whole. In this review we summarize the state of the art about the microbiome nose-mouth connection in AR to understand how environmental stimuli change the microbiota composition as well as how an imbalance can induce allergy-related inflammation. This review follows a narrative approach. Literature was identified through systematic searches of PubMed, Web of Science, and Scopus databases (up to March 2025) using the following key terms and their combinations: “allergic rhinitis’, “nasal microbiome”, “oral microbiome”, “dysbiosis”, “epithelial barrier”, ’short-chain fatty acids’, “Th2 inflammation”, and “probiotics”. Inclusion criteria encompassed original research articles, systematic reviews, and meta-analyses published in English; conference abstracts, case reports, and purely non-human studies were excluded unless they provided mechanistic insights not available from human data. Environmental exposures substantially alter upper airway microbial communities. Air pollutants such as PM₂.₅ and diesel exhaust particles (DEP) damage epithelial tight junction proteins via reactive oxygen species (ROS), increasing nasal permeability. DEP additionally functions as an immune adjuvant by promoting pro-Th2 immune polarization. Antibiotic treatment during early childhood may affect GI tract development by altering resident bacterial populations, being considered as a strong risk factor for developing AR. On the other hand, farm exposure and microbial diversity provide protection by enhancing regulatory T cell induction. AR patients exhibit characteristic nasal dysbiosis, including overgrowth of Staphylococcus aureus and Moraxella catarrhalis alongside depletion of protective commensals such as Dolosigranulum pigrum and Corynebacterium spp. This dysbiosis disrupts the epithelial barrier, triggering alarmin release (TSLP, IL-25, IL-33) and amplifying type 2 inflammation. The oral microbiota also contributes via the oral-nasal-pulmonary axis whereby periodontal pathogens are pro-inflammatory while commensals have immunomodulatory roles. Mechanistically, microbiome-derived metabolites—especially short chain fatty acids and tryptophan derivatives—regulate the immune system via G protein-coupled receptors, histone deacetylase inhibition, and aryl hydrocarbon receptor activation. Dysbiosis promotes Th2 polarization, Treg/Th17 imbalance, and the activation of ILC2s, whereas neuro-immune interactions via TRPV1/TRPA1 enhance neurogenic inflammation. Translation to clinical opportunity: Microbiome based diagnostic biomarker; Probiotic (nasal/oral); Prebiotics; postbiotics, and engineered bacteria. Multi-omics based precision medicine using ML to stratify patient and tailor intervention. In summary, this review offers an insight into the theory of the microbiome-immunology interplay in AR as well as new avenues to consider regarding treatment of this condition through the nasal-oral microbiota axis.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/falgy.2026.1757776</guid>
        <link>https://www.frontiersin.org/articles/10.3389/falgy.2026.1757776</link>
        <title><![CDATA[Diagnostics and monitoring in Hymenoptera venom allergy: current and future perspectives]]></title>
        <pubdate>2026-04-24T00:00:00Z</pubdate>
        <category>Review</category>
        <author>Weronika Wilińska</author><author>Aleksandra Starosz</author><author>Kamil Grubczak</author>
        <description><![CDATA[Hymenoptera stings are a major trigger of IgE-mediated anaphylaxis, yet only a minority of exposed individuals develop systemic reactions, making accurate diagnosis essential but complex. This review synthesizes current evidence across clinical, serologic, cellular and molecular diagnostic modalities in Hymenoptera venom allergy. Clinical history and epidemiologic predictors—such as occupation, cumulative sting exposure, reaction latency, comorbidities and quality-of-life impairment, provide crucial context but lack sufficient predictive power when used alone. Skin prick and intradermal testing remain first-line tools due to high sensitivity, although interpretation is limited by interspecies cross-reactivity, extract variability and reduced reliability shortly after a sting. Serum IgE and component-resolved diagnostics improve species identification but are influenced by cross-reactive carbohydrate determinants and cannot reliably predict reaction severity or venom-immunotherapy outcomes. Basal and acute tryptase measurements contribute significantly to risk stratification and detection of clonal mast-cell disorders, though normal values do not exclude severe reactions. Functional assays, including basophil activation testing, histamine-release assays and emerging mast-cell activation platforms, provide dynamic confirmation of effector-cell reactivity in diagnostically challenging cases. Controlled sting challenge remains the reference method for confirming clinical reactivity or protection but is reserved for selected high-risk patients due to inherent procedural risks. Novel biomarkers such as osteopontin, KIT mutations, PGD2 metabolites, regulatory T-cell signatures and multi-omic molecular profiles offer promising avenues for future refinement. Overall, evidence supports a multimodal, individualized diagnostic strategy integrating clinical context with complementary laboratory and functional tests.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/falgy.2026.1666241</guid>
        <link>https://www.frontiersin.org/articles/10.3389/falgy.2026.1666241</link>
        <title><![CDATA[Actual use of PROMs in asthma and rhinitis recommended by guidelines in clinical settings: PROMUSE respiratory study]]></title>
        <pubdate>2026-04-24T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Ivan Cherrez-Ojeda</author><author>Jean Bousquet</author><author>Torsten Zuberbier</author><author>Juan C. Calderon</author><author>Pavel Kolkhir</author><author>Anastasiia Allenova</author><author>Andrey Allenov</author><author>Sergey Tkachenko</author><author>Florin Mihaltan</author><author>Ruxandra Ulmeanu</author><author>Mona Al-Ahmad</author><author>Mònica Rodriguez-González</author><author>Guillermo Wakida-Kusunoki</author><author>German D. Ramon</author><author>Maia Rukhadze</author><author>Désirée E. Larenas-Linnemann</author><author>Mitja Košnik</author><author>Juan Carlos Ivancevich</author><author>Luis Felipe Ensina</author><author>Nelson A. Rosario Filho</author><author>Violeta Kvedariene</author><author>Herberto Jose Chong-Neto</author><author>Ivan Tinoco</author><author>Anna Bedbrook</author><author>Gabriela Rodas-Valero</author><author>Marco Faytong-Haro</author><author>Marcus Maurer</author><author>Oliver Pfaar</author><author>Karla Robles-Velasco</author>
        <description><![CDATA[RationaleGuidelines advise for the implementation of patient-reported outcomes (PROMs) to provide crucial insights into patients' perceptions of their disease burden, treatment needs, and quality of life. Despite their proven benefits in managing chronic respiratory diseases like asthma, allergic rhinitis (AR), and rhinosinusitis (RS), there is limited data on their adoption among physicians treating these conditions.ObjectivesOur objective is to identify the utilization patterns of PROMs, together with the reasons for their usage and the barriers to their adoption among practitioners managing patients with asthma, AR, and RS.MethodsThis was a cross-sectional observational study using a questionnaire encompassing all pertinent PROMs and disseminated to practitioners associated with the ARIA, UCARE, ADCARE, and ACARE networks. Individuals unfamiliar with PROMS or lacking prior experience with it were eliminated. Descriptive and analytical data were utilized, categorized by the frequency and type of PROMs applied. Stata 18.0 was utilized, with p < 0.05 indicating statistical significance.ResultsA total of 439 practitioners participated, with PROMs predominantly utilized by physicians certified for over 30 years and by respiratory specialists (16.67% and 12.46%, respectively; p < 0.05). Pulmonologists exhibited the greatest utilization of asthma PROMs at 86%, while allergists predominantly employed AR and RS PROMs at 38.42% and 33.33%, respectively (p < 0.001). ACT (66.74%), RCAT (27.79%), and SNOTT22 (15.26%) were the predominant PROMs utilized primarily for asthma (79.19%), AR (51.23%), and RS (57.26%), respectively (p < 0.001). The foremost purposes for their application were disease control monitoring (93.39%) and evaluation of performance of therapy approaches (90.2%). The most significant barrier identified was time constraint, rated at 75.40% (p > 0.05 across all groups).ConclusionsThe use of PROMs is suboptimal, primarily due to time limitations. It is imperative that methods be swiftly implemented to include these techniques into the therapeutic environment to attain enhanced outcomes.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/falgy.2026.1740307</guid>
        <link>https://www.frontiersin.org/articles/10.3389/falgy.2026.1740307</link>
        <title><![CDATA[The testosterone paradox in asthma]]></title>
        <pubdate>2026-04-23T00:00:00Z</pubdate>
        <category>Mini Review</category>
        <author>Ynuk Bossé</author>
        <description><![CDATA[Asthma and an excessive response to inhaled methacholine, commonly called hyperresponsiveness, are intimately linked. Therefore, factors increasing the methacholine response are expected to contribute to asthma as well. However, this is clearly not the case for testosterone, the predominant sex hormone in males. While testosterone increases the methacholine response, it is rather protective in asthma and experimental asthma. These incompatible observations are referred herein as the ‘testosterone paradox’, and the chase is now on to unravel its underlying mechanisms.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/falgy.2026.1786200</guid>
        <link>https://www.frontiersin.org/articles/10.3389/falgy.2026.1786200</link>
        <title><![CDATA[Nickel(II) sulphate–induced allergic contact dermatitis as experimental tool to investigate inflammatory pruritus in humans]]></title>
        <pubdate>2026-04-22T00:00:00Z</pubdate>
        <category>Brief Research Report</category>
        <author>Karoline Lukaschek</author><author>Kiran Kumar Bali</author><author>Konstantin Agelopoulos</author><author>Mustafa Kaplan</author><author>Sonja Ständer</author><author>Roman Rukwied</author><author>Elke Weisshaar</author>
        <description><![CDATA[Allergic contact dermatitis is a leading cause of occupational skin disease, with nickel(II) sulphate representing one of the most prevalent contact allergies worldwide. Clinically, nickel-induced dermatitis is characterised by pronounced inflammation and intense pruritus. The functional role of endogenous mediators, structural neuronal changes, and molecular mediators contributing to the generation of itch in allergic contact dermatitis still needs to be investigated. We present nickel(II) sulphate-induced contact dermatitis as a mechanistic model to investigate pruritus under controlled conditions in humans. Thereby, we can combine and correlate clinical characterisation of nickel(II) sulphate contact dermatitis with psycho-physical, structural, and molecular analyses to identify inflammatory pathways, mediator profiles, and gene regulatory pathways involved in pruritus generation. By enabling the systematic characterisation of itch mechanisms at molecular, structural, and functional, levels, this approach provides a translational scope to advance our understanding of pruritogenic pathways and for developing targeted therapeutic strategies in allergic contact dermatitis.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/falgy.2026.1846379</guid>
        <link>https://www.frontiersin.org/articles/10.3389/falgy.2026.1846379</link>
        <title><![CDATA[Editorial: Allergen cross-reactivity - a challenge in daily practice]]></title>
        <pubdate>2026-04-21T00:00:00Z</pubdate>
        <category>Editorial</category>
        <author>Marcin Kurowski</author><author>Rosemarie DeKruyff</author><author>Daniela Briceno Noriega</author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/falgy.2026.1781121</guid>
        <link>https://www.frontiersin.org/articles/10.3389/falgy.2026.1781121</link>
        <title><![CDATA[Recall urticaria caused by vedolizumab: case report and literature review]]></title>
        <pubdate>2026-04-21T00:00:00Z</pubdate>
        <category>Case Report</category>
        <author>Mio Kozuma</author><author>Reiko Hara</author><author>Yumiko Sakuragi</author><author>Natsuko Saito-Sasaki</author><author>Yu Sawada</author>
        <description><![CDATA[Recall urticaria is a rare hypersensitivity phenomenon characterized by the reappearance of urticarial wheals strictly confined to previously exposed skin sites following systemic re-exposure to a trigger. Although reported with several drugs, its clinical features and underlying mechanisms remain poorly defined. A 25-year-old man with ulcerative colitis developed acute pruritic wheals localized exclusively to prior subcutaneous injection sites approximately 15 min after intravenous administration of vedolizumab. He had experienced repeated localized injection-site reactions during prior subcutaneous therapy. Histopathology revealed mild perivascular inflammation with eosinophils. The eruption resolved spontaneously within 24 h without systemic symptoms, and vedolizumab therapy was continued. This case represents the first report of vedolizumab-associated recall urticaria. A review of previously reported cases highlights strict site specificity as the defining feature, irrespective of the route or timing of re-exposure. Recall urticaria should be recognized as a site-specific hypersensitivity reaction distinct from systemic drug allergy.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/falgy.2026.1807126</guid>
        <link>https://www.frontiersin.org/articles/10.3389/falgy.2026.1807126</link>
        <title><![CDATA[A novel nasal-to-oral airflow pressure ratio as an objective indicator of nasal obstruction]]></title>
        <pubdate>2026-04-17T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Shiqi Wang</author><author>Baoshi Fan</author><author>Yuntian Bao</author><author>Yusong Dai</author><author>Minghui Wang</author><author>Xindi Yang</author><author>Wendong Liu</author><author>Caifeng Xia</author><author>Yu Song</author>
        <description><![CDATA[ObjectiveTo introduce and clinically validate, for the first time, a novel nasal-to-oral airflow pressure ratio as an objective metric for assessing nasal obstruction. This ratio is designed to capture compensatory breathing patterns and to improve correlation with subjective symptoms compared with existing assessment methods.MethodsA total of 108 patients with self-reported nasal obstruction and 26 healthy controls were enrolled. A custom-designed face mask equipped with pressure sensors recorded nasal airflow pressure during quiet breathing and oral airflow pressure during forced oral breathing. The nasal-to-oral airflow pressure ratio was calculated and correlated with visual analogue scale (VAS) scores for nasal obstruction using Spearman's correlation. Sex-specific subgroup analyses were performed.ResultsThe nasal-to-oral airflow pressure ratio was significantly lower in patients with nasal congestion than in controls (0.13 ± 0.10 vs 0.23 ± 0.12; p < 0.001). The ratio showed a strong negative correlation with VAS scores (ρ = −0.645; p < 0.001), outperforming traditional metrics for assessing nasal obstruction. Sex-specific analyses revealed consistent trends in both males and females, with a slightly stronger correlation in female patients.ConclusionThis study provides the first clinical validation of the nasal-to-oral airflow pressure ratio as a sensitive, practical, and objective indicator of nasal obstruction. By incorporating compensatory oral breathing dynamics, the ratio bridges the gap between subjective sensation and traditional objective measurements, offering a low-cost, easy-to-deploy tool for broad clinical use.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/falgy.2026.1842074</guid>
        <link>https://www.frontiersin.org/articles/10.3389/falgy.2026.1842074</link>
        <title><![CDATA[Editorial: Allergic diseases through precision medicine]]></title>
        <pubdate>2026-04-17T00:00:00Z</pubdate>
        <category>Editorial</category>
        <author>Patricia Agudelo-Romero</author><author>Enza D'Auria</author><author>Anthony Bosco</author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/falgy.2026.1783914</guid>
        <link>https://www.frontiersin.org/articles/10.3389/falgy.2026.1783914</link>
        <title><![CDATA[Hereditary α-tryptasemia; a review of mechanisms linking α-tryptase gene dosage to intestinal homeostasis and immunopathology]]></title>
        <pubdate>2026-04-14T00:00:00Z</pubdate>
        <category>Review</category>
        <author>Ilaria M. Simeone</author><author>Michelle Galeas-Pena</author><author>Katelyn White</author><author>Brandy Sullivan</author><author>Alexandra Morelli</author><author>Jocelyn A. Silvester</author><author>Liza Konnikova</author><author>Amelie Therrien</author><author>Sarah C. Glover</author>
        <description><![CDATA[Hereditary α-tryptasemia (HαT) is a genetic trait characterized by increased TPSAB1 copy number. Identified in 2015, the HαT trait impacts approximately 4%–6% of individuals of European ancestry and manifests with core clinical features in one-third of individuals who test positive for the genetic trait. HαT represents a natural human model of α-tryptase overexpression which can be leveraged to better and more comprehensively understand tryptase and mast cell (MC) biology at the tissue level. In this review, we synthesize emerging evidence demonstrating that HαT is a clinically significant modifier of disease in the gastrointestinal (GI) tract. We summarize findings demonstrating that HαT impacts small intestinal immunopathology even in the absence of overt GI pathology. In celiac disease, coexisting HαT is associated with increased duodenal MCs and persistent GI symptoms (diarrhea, bloating, abdominal pain) despite a gluten-free diet. We also review emerging data indicating that HαT may act as a disease modifier in inflammatory bowel disease (IBD); increased α-tryptase gene dosage is associated with intestinal MC activation and increased expression of MRGPRX2. These changes may amplify MC–mediated inflammatory pathways within the intestinal mucosa and contribute to the complexity of immune signaling traditionally attributed to T-cell–driven inflammation in IBD. Taken together, emerging modern cellular and molecular biology evidence suggests that the natural overexpression of α-tryptase in HαT alters MC behavior and GI intestinal immunopathology, thereby modifying disease outcomes across a spectrum of GI illnesses.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/falgy.2026.1760856</guid>
        <link>https://www.frontiersin.org/articles/10.3389/falgy.2026.1760856</link>
        <title><![CDATA[Digital health in allergy care: current practices, evidence, and future prospects]]></title>
        <pubdate>2026-04-14T00:00:00Z</pubdate>
        <category>Mini Review</category>
        <author>Olga Lourenço</author><author>Adriano N. Raposo</author>
        <description><![CDATA[This mini-review summarizes the current applications of digital tools in allergy care, including telemedicine platforms, mobile health technologies, and AI-based decision support systems. It critically examines available evidence, benefits, and challenges for clinical practice and outlines future directions for integrating digital health into personalized allergy management. Mobile apps and wearable sensors enable real-time tracking of symptoms, medication use, and environmental triggers, providing actionable data that supports proactive disease management. Continuous data streams enhance clinicians’ ability to adjust treatment promptly and personalize care. AI-driven tools offer emerging opportunities for predictive modeling and decision support, while telemedicine expands access and convenience. Together, these innovations may support more patient-centered, equitable, and data-informed care.]]></description>
      </item>
      </channel>
    </rss>